Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design Article

cited authors

  • Catenacci, Daniel V. T.; Tesfaye, Anteneh; Tejani, Mohamed; Cheung, Eric; Eisenberg, Peter; Scott, Aaron J.; Eng, Clarence; Hnatyszyn, James; Marina, Neyssa; Powers, Janine; Wainberg, Zev

authors

Publication Date

  • June 1, 2019

webpage

published in

category

keywords

  • FGFR2 amplification bemarituzumab
  • Phase III study design
  • gastric and esophageal adenocarcinoma

start page

  • 2073

end page

  • 2082

volume

  • 15

issue

  • 18